Related references
Note: Only part of the references are listed.Novel modified leucine and phenylalanine dipeptides modulate viability and attachment of cancer cells
Radek Jorda et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome
Qi Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma
Yi Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases
Advait Nagle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides
Wenhu Zhan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors
Jianjun Yu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Preparation and biological evaluation of soluble tetrapeptide epoxyketone proteasome inhibitors
Meng Lei et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment
Jeffrey J. Jackson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Synthesis and Biological Activity of Peptide α-Ketoamide Derivatives as Proteasome Inhibitors
Salvatore Pacifico et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits
Bo-Tao Xin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits
Takashi Yoshida et al.
Oncotarget (2018)
NEDDylation promotes nuclear protein aggregation and protects the Ubiquitin Proteasome System upon proteotoxic stress
Chantal M. Maghames et al.
NATURE COMMUNICATIONS (2018)
Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine
Radek Jorda et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target
Philipp M. Cromm et al.
ACS CENTRAL SCIENCE (2017)
Structure-Driven Developments of 26S Proteasome Inhibitors
Pawel Sledz et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56 (2016)
Structure- and function-based design of Plasmodium-selective proteasome inhibitors
Hao Li et al.
NATURE (2016)
Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors
Eva M. Huber et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes
Gerjan de Bruin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
New 26S Proteasome Inhibitors with High Selectivity for Chymotrypsin-Like Activity and p53-Dependent Cytotoxicity
Paul M. Neilsen et al.
ACS CHEMICAL BIOLOGY (2013)
Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines
Ales Imramovsky et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites
Paul P. Geurink et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development
Eva Maria Huber et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Alexei F. Kisselev et al.
CHEMISTRY & BIOLOGY (2012)
Peptido Sulfonyl Fluorides as New Powerful Proteasome Inhibitors
Arwin J. Brouwer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Shirin Arastu-Kapur et al.
CLINICAL CANCER RESEARCH (2011)
Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors
Zhimin Lu et al.
CELL CYCLE (2010)
Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors
Michael Screen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites
Matthew Britton et al.
CHEMISTRY & BIOLOGY (2009)
Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL
Guangrong Lu et al.
CANCER BIOLOGY & THERAPY (2008)
Enantiodivergent, catalytic asymmetric synthesis of γ-amino vinyl sulfones
A Picó et al.
JOURNAL OF ORGANIC CHEMISTRY (2003)
Share Paper
